Cancer & SURVIVEiT News
Category Filter:
FDA approves brigatinib for ALK-positive metastatic NSCLC
FDA approves brigatinib for ALK-positive metastatic NSCLC On May 22, 2020, the Food and Drug Administration approved brigatinib (ALUNBRIG, ARIAD Pharmaceuticals Inc.) for adult patients with anaplastic lymphoma kinase (ALK)-positive…
FDA approves atezolizumab for first-line treatment of metastatic NSCLC with high PD-L1 expression
FDA approves atezolizumab for first-line treatment of metastatic NSCLC with high PD-L1 expression On May 18, 2020, the Food and Drug Administration approved atezolizumab (TECENTRIQ®, Genentech Inc.) for the first-line…
FDA approves nivolumab plus ipilimumab for first-line mNSCLC (PD-L1 tumor expression ≥1%)
FDA approves nivolumab plus ipilimumab for first-line mNSCLC (PD-L1 tumor expression ≥1%) On May 15, 2020, the Food and Drug Administration approved the combination of nivolumab (OPDIVO, Bristol-Myers Squibb Co.)…
FDA grants accelerated approval to capmatinib for metastatic non-small cell lung cancer
FDA grants accelerated approval to capmatinib for metastatic non-small cell lung cancer On May 6, 2020, the Food and Drug Administration granted accelerated approval to capmatinib (TABRECTA, Novartis) for adult…
FDA approves durvalumab for extensive-stage small cell lung cancer
FDA approves durvalumab for extensive-stage small cell lung cancer On March 27, 2020, the Food and Drug Administration approved durvalumab (IMFINZI, AstraZeneca) in combination with etoposide and either carboplatin or…
5-Year Study Finds Treatment To Improve Overall Survival In Advanced NSCLC
Exciting news for some patients with NSCLC: a new study has found that treatment with the PD-1 inhibitor pembrolizumab improved overall survival in patients with advanced PD-L1-positive non-small cell lung…
FDA approves entrectinib for NTRK solid tumors and ROS-1 NSCLC
FDA approves entrectinib for NTRK solid tumors and ROS-1 NSCLC On August 15, 2019, the Food and Drug Administration granted accelerated approval to entrectinib (ROZLYTREK, Genentech Inc.) for adults and…
3 Studies Show No Association Between Tumor Mutational Burden and Key Outcomes in NSCLC
The 2019 World Conference on Lung Cancer (WCLC) took place September 7-10. As the world’s largest gathering of international researchers, clinicians and scientists in the field of lung cancer, there…
FDA approves pembrolizumab for metastatic small cell lung cancer
FDA approves pembrolizumab for metastatic small cell lung cancer On June 17, 2019, the Food and Drug Administration granted accelerated approval to pembrolizumab (KEYTRUDA, Merck) for patients with metastatic small…
- « Previous
- 1
- 2
- 3
- Next »